Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome

被引:33
|
作者
Calemma, Rosa [1 ]
Ottaiano, Alessandro [1 ]
Trotta, Anna Maria [1 ]
Nasti, Guglielmo [1 ]
Romano, Carmela [1 ]
Napolitano, Maria [1 ]
Galati, Domenico [1 ]
Borrelli, Pasquale [1 ]
Zanotta, Serena [1 ]
Cassata, Antonino [1 ]
Castello, Giuseppe [2 ]
Iaffaioli, Vincenzo Rosario [1 ]
Scala, Stefania [1 ]
机构
[1] Natl Canc Inst G Pascale, I-80131 Naples, Italy
[2] CROM Ctr Ric Oncol Mercogliano, Mercogliano, AV, Italy
来源
JOURNAL OF TRANSLATIONAL MEDICINE | 2012年 / 10卷
关键词
Fc gamma receptor; Colorectal cancer; Prognosis; Cetuximab; Panitumumab; Antibody-dependent cell-mediated cytotoxicity; CELL-MEDIATED-CYTOTOXICITY; MONOCLONAL-ANTIBODIES; KRAS MUTATIONS; CETUXIMAB; RIIIA; IMPACT;
D O I
10.1186/1479-5876-10-232
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Anti-EGFR monoclonal antibodies have shown efficacy in the treatment of metastatic colorectal cancer (mCRC). One of the mechanism is the antibody-dependent cell-mediated cytotoxicity (ADCC) in which Fc region of the antibody binds to the Fc gamma receptors (Fc gamma R) expressed by immune cells. The present study investigated the association between single nucleotide polymorphisms of Fc gamma RIIa and Fc gamma RIIIa and clinical outcome in mCRC treated with anti-EGFR antibodies. Methods: Seventy-four consecutive patients with mCRC were analyzed. The genotypes for Fc gamma RIIa-131 histidine (H)/arginine (R), Fc gamma RIIIa-158 valine (V)/phenylanaline (F) polymorphisms were evaluated by directly sequencing. Multiplex allele-specific polymerase chain reaction was performed for Fc gamma RIIIa-158 valine (V)/phenylanaline (F). Correlations between Fc gamma R polymorphisms, baseline patient and tumor features were studied by contingency tables and the chi-square test. The Kaplan-Meier product limit method was applied to the progression-free survival (PFS) curves. Univariate analysis was performed with the log-rank test. Cox proportional-hazards regression was used to analyze the effect of multiple risk factors on PFS. Results: Fc gamma RIIIa polymorphisms were significantly associated with response to anti-EGFR-based therapy in 49 patients with kras wt tumors (p=0.035). There was not association with response for Fc gamma RIIa polymorphisms. Furthermore, obtained results suggested that prognosis is particularly unfavorable for patients carrying the Fc gamma RIIIa-158F/F genotype (median PFS V/V, V/F, F/F: 18.2 vs 17.3 vs 9.4 months). No prognostic ability was identified for Fc gamma RIIa polymorphisms. Conclusions: In mCRC patients the presence of Fc gamma RIIIa-F can predict resistance to anti-EGFR therapy and unfavorable prognosis.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients
    Inti Zlobec
    Francesca Molinari
    Vittoria Martin
    Luca Mazzucchelli
    Piercarlo Saletti
    Rosangela Trezzi
    Sara De Dosso
    Tatjana Vlajnic
    Milo Frattini
    Alessandro Lugli
    World Journal of Gastroenterology, 2010, 16 (38) : 4823 - 4831
  • [32] Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
    Perkins, Geraldine
    Lievre, Astrid
    Ramacci, Carole
    Meatchi, Tchao
    de Reynies, Aurelien
    Emile, Jean-Francois
    Boige, Valerie
    Tomasic, Gorana
    Bachet, Jean-Baptiste
    Bibeau, Frederic
    Bouche, Olivier
    Penault-Llorca, Frederique
    Merlin, Jean-Louis
    Laurent-Puig, Pierre
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (06) : 1321 - 1331
  • [33] Clinical results: a fully human anti-EGFr antibody in patients with advanced cancer.
    Figlin, R
    Belldegrun, A
    Crawford, J
    Lohner, M
    Roskos, L
    Yang, X
    Schwab, G
    Weiner, L
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3785S - 3785S
  • [34] Rechallenge with anti-EGFR antibodies in metastatic colorectal cancer: A single center analysis
    Duarte Mendes, A.
    Vicente, R.
    Caleca, T.
    Silva, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S149 - S149
  • [35] Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
    Fakih, Marwan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (09) : 1471 - 1480
  • [36] Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era
    Eric Van Cutsem
    Sabine Tejpar
    Targeted Oncology, 2008, 3 : 223 - 225
  • [37] Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies
    Lievre, Astrid
    Laurent-Puig, Pierre
    PERSONALIZED MEDICINE, 2009, 6 (02) : 145 - 157
  • [38] Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era
    Van Cutsem, Eric
    Tejpar, Sabine
    TARGETED ONCOLOGY, 2008, 3 (04) : 223 - 225
  • [39] MicroRNAs and response to anti-EGFR therapy in metastatic colorectal cancer.
    Blanco-Calvo, Moises
    Haz-Conde, Mar
    Rodriguez-Rigueiro, Teresa
    Figueroa, Angelica
    Reboredo, Margarita
    Medina Villaamil, Vanessa
    Lorenzo-Patino, Maria J.
    Arnal, Francisco
    Anton-Aparicio, Luis
    Alonso-Jaudenes Curbera, Guillermo
    Valladares-Ayerbes, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
    Mata-Molanes, Juan J.
    Rebollo-Liceaga, Joseba
    Martinez-Navarro, Elena M.
    Manzano, Ramon Gonzalez
    Brugarolas, Antonio
    Juan, Manel
    Sureda, Manuel
    FRONTIERS IN ONCOLOGY, 2022, 12